References
- Bruchim I, Ben-Harim Z, Piura E, et al. (2016). Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer. J Chemother 28:129–34.
- Burke TG. (1996). Chemistry of the camptothecins in the bloodstream. Drug stabilization and optimization of activity. Ann NY Acad Sci 803:29–31.
- Dahan A, Hoffman A. (2005). Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci 24:381–8.
- Emerson DL, Besterman JM, Brown HR, et al. (1995). In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res 55:603–9.
- Gavrieli Y, Sherman Y, Bensasson SA. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501.
- Giovanella BC, Harris N, Mendoza J, et al. (2000). Dependence of anticancer activity of camptothecins on maintaining their lactone function. Ann NY Acad Sci 922:27.
- Giovanella BC, Hinz HR, Kozielski AJ, et al. (1991). Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51:3052–5.
- Giovanella BC, Stehlin JS, Wall ME, et al. (1989). DNA topoisomerase I–targeted chemotherapy of human colon cancer in xenografts. Science 246:1046–8.
- Hagmann R, Hess V, Zippelius A, Rothschild SI. (2015). Second-line therapy of small-cell lung cancer: topotecan compared to a combination treatment with adriamycin, cyclophosphamide and vincristine (ACO) – a single center experience. J Cancer 6:1148–54.
- Herben VM, Ten Bokkel Huinink WW, Beijnen JH. (1996). Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31:85–102.
- Hsiang YH, Hertzberg R, Hecht S, Liu LF. (1985). Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–8.
- Lozano GM, Bejarano I, Espino J, et al. (2009). Relationship between caspase activity and apoptotic markers in human sperm in response to hydrogen peroxide and progesterone. J Reprod Dev 55:615–21.
- Nicum SJ, O’Brien ME. (2007). Topotecan for the treatment of small-cell lung cancer. Expert Rev Anticancer Ther 7:795–801.
- Ozols RF. (2000). Optimum chemotherapy for ovariancancer. Int J Gynecol Cancer 10:33–7.
- Padhi S, Mirza MA, Verma D, et al. (2016). Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential. Drug Deliv 23:2827–37.
- Qin L, Zhang F, Lu X, et al. (2013). Polymeric micelles for enhanced lymphatic drug delivery to treat metastatic tumors. J Control Release 171:133–42.
- Sai K, Kaniwa N, Ozawa S, Sawada JI. (2002). An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry. Biomed Chromatogr 16:209–18.
- Saltz LB, Cox JV, Blanke C, et al. (2001). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 344:306–7.
- Sawada S, Okajima S, Aiyama R, et al. (1991). Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull (Tokyo) 39:1446–50.
- Trevaskis NL, Charman WN, Porter CJH. (2008). Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 60:702–16.
- Wethington SL, Wright JD, Herzog TJ. (2008). Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert Rev Anticancer Ther 8:819–31.
- Zhang G, Wang T, Gao L, Quan D. (2013). Oral delivery of oil-based formulation for a novel synthetic cationic peptide of GnRH (gonadotropin-releasing hormone) antagonist for prostate cancer treatment. Int J Pharm 450:138–44.